These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10767456)

  • 41. The effect of intravesical capsaicin and resiniferatoxin in neurogenic bladder dysfunction.
    el-Mahrouky AS; Elashry OM; Emran MA
    Adv Exp Med Biol; 2003; 539(Pt A):359-79. PubMed ID: 15088918
    [No Abstract]   [Full Text] [Related]  

  • 42. Treatment of overactive bladder with modified intravesical oxybutynin chloride.
    Saito M; Tabuchi F; Otsubo K; Miyagawa I
    Neurourol Urodyn; 2000; 19(6):683-8. PubMed ID: 11071699
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intravesical capsaicin in patients with detrusor hyper-reflexia--a placebo-controlled cross-over study.
    Petersen T; Nielsen JB; Schrøder HD
    Scand J Urol Nephrol; 1999 Apr; 33(2):104-10. PubMed ID: 10360450
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness of intravesical resiniferatoxin for anticholinergic treatment refractory detrusor overactivity due to nonspinal cord lesions.
    Kuo HC
    J Urol; 2003 Sep; 170(3):835-9. PubMed ID: 12913711
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The medical treatment of overactive bladder].
    Beneton C; De Parisot O
    Neurochirurgie; 2003 May; 49(2-3 Pt 2):369-76. PubMed ID: 12746713
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways.
    Kim Y; Yoshimura N; Masuda H; de Miguel F; Chancellor MB
    Urology; 2005 Feb; 65(2):238-42. PubMed ID: 15708029
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Electromotive drug administration of lidocaine to anesthetize the bladder before intravesical capsaicin.
    Dasgupta P; Fowler CJ; Stephen RL
    J Urol; 1998 Jun; 159(6):1857-61. PubMed ID: 9598475
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravesical treatment of bladder dysfunction.
    Zimmern P
    J Urol; 2001 Dec; 166(6):2241. PubMed ID: 11696743
    [No Abstract]   [Full Text] [Related]  

  • 49. Pharmacological agents for the treatment of urinary incontinence due to overactive bladder.
    Wein AJ
    Expert Opin Investig Drugs; 2001 Jan; 10(1):65-83. PubMed ID: 11116281
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of intravesical oxybutynin on the ice water test and on electrical perception thresholds in patients with neurogenic detrusor overactivity.
    Van Meel TD; De Wachter S; Wyndaele JJ
    Neurourol Urodyn; 2010 Mar; 29(3):391-4. PubMed ID: 19787712
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multiple intravesical instillation of low-dose resiniferatoxin is effective in the treatment of detrusor overactivity refractory to anticholinergics.
    Kuo HC
    BJU Int; 2005 May; 95(7):1023-7. PubMed ID: 15839924
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of intravesical Resiniferatoxin (RTX) on lower urinary tract symptoms, urodynamic parameters, and quality of life of patients with urodynamic increased bladder sensation.
    Apostolidis A; Gonzales GE; Fowler CJ
    Eur Urol; 2006 Dec; 50(6):1299-305. PubMed ID: 16697519
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intravesical oxybutynin: practicalities of clinical use.
    Guerrero K; Emery S; Owen L; Rowlands M
    J Obstet Gynaecol; 2006 Feb; 26(2):141-3. PubMed ID: 16483973
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A light- and electron-microscopic histopathological study of human bladder mucosa after intravesical resiniferatoxin application.
    Silva C; Avelino A; Souto-Moura C; Cruz F
    BJU Int; 2001 Sep; 88(4):355-60. PubMed ID: 11564021
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury.
    Pannek J; Sommerfeld HJ; Bötel U; Senge T
    Urology; 2000 Mar; 55(3):358-62. PubMed ID: 10699610
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New therapeutic options for refractory neurogenic detrusor overactivity.
    Giannantoni A; Mearini E; Di Stasi SM; Costantini E; Zucchi A; Mearini L; Fornetti P; Del Zingaro M; Navarra P; Porena M
    Minerva Urol Nefrol; 2004 Mar; 56(1):79-87. PubMed ID: 15195033
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Urodynamic effects of the bladder C-fiber afferent activity modulation in chronic model of overactive bladder in rats.
    Juszczak K; Ziomber A; Wyczolkowski M; Thor PJ
    J Physiol Pharmacol; 2009 Dec; 60(4):85-91. PubMed ID: 20065501
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of neurogenic bladder dysfunction in infants and children with neurospinal dysraphism with clean intermittent (self)catheterisation and optimized intravesical oxybutynin hydrochloride therapy.
    Buyse G; Verpoorten C; Vereecken R; Casaer P
    Eur J Pediatr Surg; 1995 Dec; 5 Suppl 1():31-4. PubMed ID: 8770576
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intravesical capsaicin in neurologic impaired patients with detrusor hyperreflexia.
    Das A; Chancellor MB; Watanabe T; Sedor J; Rivas DA
    J Spinal Cord Med; 1996 Jul; 19(3):190-3. PubMed ID: 8819028
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expanded followup of intravesical oxybutynin chloride use in children with neurogenic bladder.
    Kaplinsky R; Greenfield S; Wan J; Fera M
    J Urol; 1996 Aug; 156(2 Pt 2):753-6. PubMed ID: 8683776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.